all participants experience the rapid progress and the ability to co-steer iterative development, and once this agile team experience is established the project can only succeed.
About the Authors
Jochen Scheel , Director of Software Development, and Stefan Meier , Associate Director, work as part of XDx's Information Sciences Department.
Founded in 2000, XDx Inc., a molecular diagnostics company from Brisbane, California, is on the fast track to a new era in personalized medicine. XDx focuses on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary new method of utilizing gene expression that provides additional options to current patient management by physicians specializing in these disease areas. This work is the basis for AlloMap® Molecular Expression Testing.
One of the first companies to develop and bring to market products and therapies derived from the fundamental Human Genome Project, XDx has devised a new method for non-invasively monitoring the immune system by measuring gene expression in a patient's peripheral blood. This technology has huge potential to decrease healthcare costs and improve the quality of life for patients suffering from a variety of immune-mediated diseases.